a-ULaB is a laboratory specialized in the identification of asbestos fibres presents in bulk samples and air samples. Established in 2011, this spin-off of the Université libre de Bruxelles (ULB) and of the Erasmus Hospital is the result of the medical profession and the sector of construction.
AMIA Systems is a operational excellence company developing its own software, SIMOGGA, to visualize, quantify and optimize the operations of Production plants, Maintenance sites, Distribution centers or Warehouses.
Our goals? Remove the complexity of the analysis, involve the teams to facilitate the change management and accelerate the process of change.
Antigon is a MedTech-IVD spinoff from ULB, aiming to improve blood safety transfusion by developing and launching at global level, a new disruptive Point of Care Testing device, allowing caregivers to perform instantly a crossmatching, at the bedside, of ABO groups of the patient and transfusion bag with full reliability.
Apaxen is a preclinical stage biotechnology company developing a unique class of anti-inflammatory therapeutics with a primary focus on pulmonary arterial hypertension (PAH).
Aquilon Pharmaceuticals develops innovation inhaled formulations for the treatment of asthma and COPD.
BePharBel Manufacturing produces, on pilot project or industrial scale, pharmaceutical and para-pharmaceutical products in a range of galenic forms: Liquid forms (syrups, nasal sprays, sterile vials), Dry forms (tablets, granules, capsules, sterile powders), Pasty forms (creams, ...)
BIO.be constitue une interface privilégiée entre l’expertise de l’Institut de Pathologie et Génétique (IPG) et le monde extérieur : laboratoires universitaires, institutions diverses impliquées dans la recherche en général (fondamentale ou, plus souvent, appliquée) ou encore avec l’industrie pharmaceutique dans le cadre d’études cliniques, tests libérations de lots cliniques…
BioWin, the Health Cluster of Wallonia is the regional reference player for all the stakeholders (companies, research centers and universities) involved in innovative R&D projects and/or skills development in the field of health biotechnology and medical technologies.
Bioxodes is a biotech start-up specialized in the development of novel therapeutics using molecules from nature dedicated to prevent thrombosis and inflammatory processes.
Bone Therapeutics is a bone cell therapy company specializing in addressing unmet medical needs in the field of orthopaedics and bone diseases.
Bone Therapeutics has a broad portfolio of innovative allogeneic cell therapy solutions across a range of indications.
Caprion Biosciences, is a leading specialty clinical research organization (CRO) laboratory providing state-of-the-art integrated platforms in proteomics and immune monitoring services to the pharmaceutical and biotechnology industry.
The CMMI is an integrated preclinical imaging facility which provides services and training for academic and industrial partners. Our multidisciplinary team offers a wide range of services, covering the entire workflow: sample preparation, image acquisition and analysis.
The CMMI was established with the financial support of the European Union and the Walloon Region (FEDER program) and is located in the BioPark Charleroi Brussels South, a site which hosts two academic institutes and several companies active in the field of life sciences.
The Centre Hospitalier Universitaire Ambroise Paré is the general public hospital of the City of Mons and its district. It is part of the intermunicipal Centre Hospitalier Universitaire et Psychiatrique de Mons-Borinage and offers a wide range of general and specialised hospital care and services for both adults and children.
Saint-Pierre University Hospital is a local public hospital, offering high quality care accessible to all, regardless of origin, philosophical or religious beliefs or patients' social condition. In this context, we take up the challenges of public health on a daily basis while declining our academic character through active involvement in teaching and research.
Saint-Pierre University Hospital is part of the Centre Hospitalier Universitaire de Bruxelles (CHUB), which brings together the public and university hospitals in Brussels (CHU Brugmann, HUDERF, Institut Jules Bordet).
Le Centre Hospitalier Universitaire de Charleroi est un hôpital public géré par l'ISPPC (Intercommunale de Santé Publique du Pays de Charleroi).
Dans la perspective régionale de valorisation, de simplification et d’optimisation de l’offre de service aux entrepreneurs pour le développement économique de la Wallonie et dans la foulée de la dynamique initiée par le plan CATCH, Charleroi Entreprendre est le fruit de l’union des équipes d'animation économique du CEEI Héraclès, d'Igretec et du Switch coworking.
Within the CHC network, Clinique Saint-Joseph is the reference point for heavy adult services: oncology, radiotherapy, cardiac coronary angiography, heavy abdominal surgery, neurosurgery, orthopedics, interventional imaging, PET-scan, MRI, Stroke Unit....
The clinic has 335 beds and employs about a thousand people (staff and freelancers).
ChromaCure’s mission is to discover and develop first-in-class small molecule therapeutics for unmet needs in oncology.
UCL Namur University Hospital and its Integrated Network of Care and Services are the result of the merger, in 2016, of the Dinant Godinne | UCL Namur University Hospital and the Sainte-Elisabeth Clinic and Maternity Hospital. Located in the province of Namur, the new entity is spread over the hospital sites of Dinant, Godinne and Sainte-Elisabeth. In addition to hospital activities, the UCL Namur University Hospital has facilities for the accommodation of the elderly and early childhood care.
With more than 4,500 employees (including 500 doctors), the UCL Namur University Hospital offers a complete range of care and services to its patients.
The Centre Hospitalier Universitaire de Charleroi is a public hospital managed by the ISPPC (Intercommunale de Santé Publique du Pays de Charleroi).
The mission of the CHU: to offer quality care and hospitality to all.
CITIUS ENGINEERING is specialised in the design and production of custom machines and means of production. It is also a research unit providing guidance and consulting services for the entire industry.
Established in the north of Charleroi, Clinique Notre-Dame de Grâce has chosen to remain a friendly hospital close to people where patients, both in their medical and personal dimensions, are at the heart of its concerns.
Clinique Saint-Pierre Ottignies is a regional reference hospital centre whose mission is to take care of patients who entrust their health to it. They are at the centre of all our attention and at the basis of all investments and recruitments, as well as of our permanent concern for improvement and our desire to transmit this vocation.
CRNA is specialised in secondary packaging activities and operates as contractor in a B2B environment for pharmaceutical industry. The secondary packaging operations are carried out in cleanrooms (class 100.000).
With a core business in plasmid DNA and genetic engineering, Delphi Genetics provides services based on unique technologies. To assist you in your viral, and non-viral, gene therapy programs, our dedicated team of scientists develop customized GMP plasmid DNA manufacturing solutions.
Our patented STABY® technology without antibiotic resistance gene is the ideal alternative to standard antibiotic-resistance selection and drives better plasmid DNA stabilization.
Provides Engineering Services and GMP/Validation Consulting Services in the pharmaceutical and biotechnology industries (or based on similar technologies): aseptic production areas, hospital pharmacy, controlled environments or critical and ultra-pure utilities, and specialized laboratories with high level of constraints: clean rooms, biological or radioactivity containment, climatic chambers, animal facilities and disinfection systems.
Endo Tools Therapeutics (ETT) is a privately held medical device company in Gosselies, Belgium. ETT is dedicated to the development of innovative devices providing new means of therapeutic interventions for gastroenterologists.
It is a spin-off from Université libre de Bruxelles, based on a collaboration between the engineers of the engineering school and the gastroenterologists from Erasme Hospital.
EPICS Therapeutics is a new and rapidly progressing drug discovery company based in Belgium. Current research focus is on the targeting of epigenetic mechanisms involved in cancer development. Our business objectives consist in the discovery and development of novel clinical agents targeting serious unmet medical needs in oncology.
The hospital is located on the Erasmus Faculty Hospital Campus, which includes the Faculty of Medicine, the Faculty of Motor Sciences and the School of Public Health. The main areas of excellence of Erasmus Hospital are : The Neurosciences, Psychiatry, Medical and surgical, gastroenterology, Cardiovascular and pulmonary sectors, Gynecology-Obstetrics. The Genetics, Transplantation and Intensive Care.
The leading pan-European exchange with global reach and local presence.
Fund+ is an open-ended Fund for long term equity investment in innovative Life Sciences companies with a focus on Belgium. We want to create sustainable shareholders value, contribute to the development of a leadership position in the Life Sciences sector and generate a tangible, beneficial societal impact.
An innovative response to the challenge of financing global health research and development.
At GHO Capital we understand healthcare trends and opportunities which enables us to identify, invest in and build fast-growing, dynamic businesses. With attractive fundamentals and a shift in market dynamics, we recognise the significant potential in European healthcare and have prioritised our focus on high growth segments.
Société de gestion de fonds d'investissements FPCI dédiés aux sociétés innovantes du Grand Ouest : Bretagne, Pays de la Loire, Normandie et Centre-Val de Loire.
Graftys is an innovation-driven Medtech company committed to the development and manufacturing of synthetic bone biomaterials. Graftys markets products covered by a large patent portfolio in more than 25 countries throughout the world, with regulatory approvals in Europe, the USA, Canada, North and South America and Australia.
The Grand Hôpital de Charleroi now includes 6 hospital sites, 4 consultation centres and various support services. In all, it represents more than 4,500 people in all specialties and professions. It is the second largest employer in Charleroi.
The Grand Hôpital de Charleroi is one of the largest private hospitals in Wallonia. Its state-of-the-art hospital activities and the competence of its specialists make it a complete hospital. It offers optimal and quality care for a wide range of pathologies and traumas.
Since 2003, Great Point Partners has focused on helping growing health care businesses achieve their full potential. We manage two separate, but highly complementary investment strategies – lower middle market growth buyout funds investing in private health care companies and a hedge fund investing in public life sciences companies.
Haute Ecole Louvain en Hainaut (Helha)
Heart Kinetics develops a cardiac remote patient monitoring system based on cutting-edge ballisto-seismocardiography for the prevention of heart failure.
HeLSci, ULB Center for Continuous Education in Health and Life Sciences
Centre Hospitalier Jolimont has more than 125 years of expertise and state-of-the-art techniques, with qualified staff and heavy services, for multidisciplinary patient care. He is forward-looking and constantly looking for new features and improvements.
Intercommunale pour la gestion et la réalisation d'études techniques et économiques.
ImmunXperts offers a wide range of – in silico and in vitro - immunology services with a strong focus on immunogenicity, cell therapy and immuno-oncology.
InhaTarget Therapeutics develops innovative and targeted dry powders for inhalation (DPI) that aim to improve the treatment of severe and/or chronic respiratory diseases.
The Innovation Fund sa/nv invests in innovative startups and companies active in the field of chemistry and life sciences.
Research at IMI focuses on enhancing basic knowledge of the cross-talk between innate and adaptive immune responses in order to set up new immunotherapeutic strategies and assess their effectiveness. The IMI conducts research in four areas of medical immunology: the development of the immune system, viral infections, vaccinology and transplantation.
Institute of Molecular Biology and Medecine (IBMM)
Inventures Investment Partners (IIP) is a management company that manages the impact venture capital funds, Inventures I and Inventures II. IIP's mission is to produce attractive financial and social returns.
L’IPG est spécialisé dans le diagnostic médical en matière d’Anatomopathologie, de Génétique, de Biologie Moléculaire & Cellulaire et Microbiologie Moléculaire.
L’Institut National des Radioéléments (IRE) (National Institute for Radioelements), with its subsidiary IRE ELiT, is an internationally recognized company, focused on the development and marketing of innovative services devoted to human healthcare and protection of the environment.
iTeos Therapeutics is targeting the tumor microenvironment to enhance the effectiveness of immune cells at eradicating cancer.
Itochu is one of the largest Japanese sogo shosha (general trading company).
Johnson & Johnson is now the world's largest and most important healthcare company. Every day, more than 130,000 employees around the world combine heart, science and ingenuity to fundamentally change the trajectory of health for humanity.
The Laboratoire de biotechnologie végétale (LBV) seeks to understand the molecular mechanisms that control vegetable development and its interactions with the environment.
The purpose of Life Sciences Research Partners is, without any profit making intentions, to carry out, promote and support scientific research in general and biomedical and biotechnological research in particular.
Lys Medical develops an endoscopic decision-aid device for airway physicians.
MaSTherCell S.A. is a dynamic and global Contract Development and Manufacturing Organization (CDMO) on a mission to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market.
Medidee is a consulting firm in the field of Clinical and Regulatory Affairs and Quality Assurance. Its services cover all steps of product development, from initial project idea to certification or regulatory clearance.
With sites in Belgium, Switzerland, Germany, Denmark and USA, Medidee is a global services supplier servings companies of all sizes ranging from academic startups to majors.
Minoryx Therapeutics is a clinical stage biotech company leading the development of new therapies for X-ALD and other Orphan CNS diseases, a group of rare diseases of genetic origin with a high unmet medical need. The company’s leading program, a differentiated PPAR gamma agonist (MIN-102), is a candidate for X-linked Adrenoleukodystrophy that has successfully completed phase 1 clinical trials and is now in a pivotal phase 2/3 trial. Minoryx harnesses its unique mechanism of action for potential use in X-ALD, a genetic disease characterized by progressive neurological deterioration with no available pharmacological treatment.
Minoryx is also working on expanding the use of MIN-102 into other CNS diseases.
MPM Capital is a healthcare investment firm with over two decades of experience founding and investing in life-sciences companies that seek to translate scientific innovations into cures for major diseases. With its experienced and dedicated team of investment professionals and Executive Partners, MPM strives to power novel medical breakthroughs that transform patients’ lives.
Ncardia is a stem cell drug discovery & development company operating worldwide with facilities and offices in Belgium, the Netherlands, and the USA. Ncardia is built on the belief and trust that stem technology will help to get better medicines to patients faster. The goal of the company is to be the supportive and trusted partner for scientists operating in the hiPSC drug discovery and development space including cardiovascular and neural safety and efficacy studies.
New Science Ventures, LLC (NSV) is a leading venture capital firm focused on building companies that leverage breakthrough science to create extraordinary value. NSV invests in companies using science-based innovations to address market needs in Life Sciences (pharmaceuticals, biologics, medical devices, and diagnostics) and Information Technology (e.g., high-performance semiconductors, cellular infrastructure, sensor networks, enterprise software, and storage) sectors.
Newton Biocapital is a Venture Capital Fund incorporated in Belgium, focused on financing biotech and life science projects in the "core of Europe" (B, NL, D, F) and Japan for the prevention and treatment of chronic diseases.
Novasep is a leading provider of services in the field of molecule production and purification for the life science and chemical industries, based on an unrivalled pool of specialized technologies.
Our unique business model addresses our customers’ manufacturing strategies, and is based on 2 sets of offerings for 7 markets.
With 1,200 employees, Novasep is established in Europe, Asia and North America and is constantly expanding its presence to better serve its customers.
Ogeda is specialising in G-Protein Coupled Receptors (GPCR) used in pharmacological response. The company runs its own research programmes in order to identify and develop candidates for original medication, particularly for use in the fields of metabolism, inflammation, and female health (e.g. endometriosis).
At OncoDNA we strive to help cancer patients. OncoDNA offers solutions combining the most relevant molecular technologies in order to provide a comprehensive characterization of the patient’s cancer, hence supporting oncologists in their treatment and follow-up decisions.
Polyris assists Seveso companies in managing their risk of major accidents and complying with the related legal requirements.
Spin-off of the University of Mons (UMONS), Polyris develops and applies the latest and most scientific methodologies.
Promethera Biosciences is committed to bring patients life-saving treatments to reduce the need for liver transplantation.
Quality Assistance is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.
Inaugurated in 1986, Queen Fabiola Children's University Hospital is the only Belgian university hospital entirely reserved for children's medicine : all is conceived for them and for their parents.
From birth to adolescence, the children receive there the most complete care.
Cliniques universitaires Saint-Luc is the largest hospital of Brussels, with 5800 employees and more than 900 beds. Beyond providing optimal patient care, Saint-Luc partners with the Université Catholique de Louvain (UCLouvain) in activities centered on research, innovation and teaching.
Saint-Luc provides reference care and treat serious, rare or complex diseases of patients in Belgium and abroad.
Sambrinvest is the financial partner of SMEs in the Charleroi Sud-Hainaut region.
SFPI-FPIM is the federal public holding company, which fulfils a dual function. It not only acts as an investment company, but also as a government holding company. The investments as a public holding company are done in consultation with the government. In addition to the public holding function, SFPI-FPIM can also acquire equity in companies at the explicit request of the federal government. These are the so-called delegated assignments.
Ackermans & van Haaren is an independent and diversified group aiming at creating shareholder value through long-term investments in a limited number of companies with growth potential on an international level.
Spectralys Biotech offers innovative FTIR-based analytical solutions for chemicals, pharmaceuticals and biologics.
SRIW develops a wide range of tailored financing solutions to support all types of project: business creation, development through innovation or investment, organic growth requiring an increase in working capital, acquisitions, establishment of a subsidiary in Wallonia, Belgium or abroad, new markets, transfers and so on.
Sterigenics is the global leader in comprehensive sterilization solutions serving customers across the medical device, pharmaceutical, commercial, and food industries.
SYnAbs SA, « Singular Antibodies », is one-stop-shop CRO, generating and manufacturing innovative monoclonal antibodies for In Vitro Diagnostic and Biopharmaceutical R&D applications. Thanks to unique proprietary technologies, SYnAbs can develop rat and guinea pigs mAbs of extreme specificity and higher affinity.
The ButterFly Fund is a pre-seed fund bridging the gap between R&D grants and seed rounds, co-created by Life Science Research Partners, Sambrinvest and Theodorus with the objective of supporting the transformation of disruptive science into innovative companies much earlier.
At TheClubDeal.com, we link Investors and Entrepreneurs around promising investment opportunities. For each of these, we will invest ourselves and co-invest with a selected number of investors.
We add value by processing strong applied governance principles, when selecting and managing our investments, and by gathering the necessary skills to successfully grow the businesses and real-estate projects we co-invest into.
Theodorus is the spin-off fund of Université Libre de Bruxelles. The first Theodorus fund was created in 2003 as a result of ULB willingness to dedicate specific resources (funding and human resources) to its spin-offs. Since then, every Theodorus Investment Funds created have had the same priority access to ULB R&D outcomes and spin-offs.
Theodorus funds II & III were created in 2006 and 2013 with a priority access to ULB R&D outcomes and spin-offs.
TheraVet S.A. is a Walloon biotech company, created in November 2017 which develops innovative treatments for high unmet medical need osteoarticular conditions (e.g., joint, tendon/ligament and bone) for small companion animals such as dogs.
TheraVet's mature product portfolio is composed of biological as well as synthetic products developed from clinical stage and marketed human products.
ULB, Université Libre de Bruxelles
Univercells is a technology company offering novel biomanufacturing platforms, aimed at increasing the availability and affordability of biologics – recombinant proteins and vaccines – for all. Univercells designs innovative production processes to significantly decrease the size of the necessary equipment and facility, for a lower capital and operational cost.
The hospital contains adult and child care services, as well as a polyclinic. It is above all the Centre for Reproductive Medicine (Centrum voor Reproductieve Geneeskunde) which is internationally recognised for its pioneering role in reproductive techniques. The hospital's emergency department is considered to be the largest emergency department in Flanders.
Vesalius Biocapital Partners invests in companies active in human health through venture capital funds. With more than € 150 million under management in two funds. Vesalius Biocapital Partners plays the role of lead investor in the large majority of its financing rounds. Vesalius’ investment strategy is focused on three areas: therapeutics, medical devices and diagnostics.
The Wallonia Export-Investment Agency (AWEX) is a Public Interest Organisation in Wallonia. It is the complete partner for all Walloon companies wishing to develop overseas and constitutes a one-stop shop for all foreign companies interested in setting up in Wallonia or expanding their existing activities.
X4C offers Innovative surface coating solutions for high-end applications.